Nothing Special   »   [go: up one dir, main page]

CZ20012058A3 - Terapeutická látka k potlačení chrápání - Google Patents

Terapeutická látka k potlačení chrápání

Info

Publication number
CZ20012058A3
CZ20012058A3 CZ20012058A CZ20012058A CZ20012058A3 CZ 20012058 A3 CZ20012058 A3 CZ 20012058A3 CZ 20012058 A CZ20012058 A CZ 20012058A CZ 20012058 A CZ20012058 A CZ 20012058A CZ 20012058 A3 CZ20012058 A3 CZ 20012058A3
Authority
CZ
Czechia
Prior art keywords
bont
clostridium toxin
carrier
added
suppressing
Prior art date
Application number
CZ20012058A
Other languages
English (en)
Other versions
CZ295769B6 (cs
Inventor
Hans Bigalke
Jürgen FREVERT
Original Assignee
Biotecon Gesellschaft Für Biotechnologische Entwic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Gesellschaft Für Biotechnologische Entwic filed Critical Biotecon Gesellschaft Für Biotechnologische Entwic
Publication of CZ20012058A3 publication Critical patent/CZ20012058A3/cs
Publication of CZ295769B6 publication Critical patent/CZ295769B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
CZ20012058A 1998-12-10 1999-12-10 Terapeutická látka k potlačení chrápání CZ295769B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19856897A DE19856897A1 (de) 1998-12-10 1998-12-10 Therapeutikum zur Unterdrückung von Schnarchgeräuschen

Publications (2)

Publication Number Publication Date
CZ20012058A3 true CZ20012058A3 (cs) 2001-09-12
CZ295769B6 CZ295769B6 (cs) 2005-11-16

Family

ID=7890562

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20012058A CZ295769B6 (cs) 1998-12-10 1999-12-10 Terapeutická látka k potlačení chrápání

Country Status (21)

Country Link
US (1) US6573241B1 (cs)
EP (1) EP1137430B1 (cs)
JP (1) JP4700811B2 (cs)
KR (1) KR100859556B1 (cs)
CN (1) CN1186095C (cs)
AT (1) ATE234108T1 (cs)
AU (1) AU764744B2 (cs)
BR (1) BR9915800A (cs)
CA (1) CA2353469A1 (cs)
CZ (1) CZ295769B6 (cs)
DE (2) DE19856897A1 (cs)
DK (1) DK1137430T3 (cs)
ES (1) ES2192880T3 (cs)
HK (1) HK1040636B (cs)
HU (1) HUP0104702A3 (cs)
IL (2) IL143528A0 (cs)
NO (1) NO328762B1 (cs)
PL (1) PL202908B1 (cs)
PT (1) PT1137430E (cs)
RU (1) RU2243783C2 (cs)
WO (1) WO2000033863A2 (cs)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
EP1898947A2 (en) * 2005-06-14 2008-03-19 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
EP1919447A4 (en) * 2005-07-18 2012-10-31 Univ Massachusetts Lowell COMPOSITIONS AND METHODS OF PREPARING AND USING NANOEMULSIONS
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CA2631927C (en) 2005-12-01 2015-08-18 University Of Massachusetts Lowell Botulinum nanoemulsions
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
CA2671133C (en) * 2006-12-01 2015-11-24 Anterios, Inc. Peptide nanoparticles and uses therefor
EP2162117B1 (en) 2007-05-31 2018-02-21 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
US20110212157A1 (en) * 2008-06-26 2011-09-01 Anterios, Inc. Dermal delivery
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US20100166739A1 (en) * 2008-12-30 2010-07-01 Lipella Paharmaceuticals Inc. Methods and Compositions for Diagnosing Urological Disorders
WO2011057301A1 (en) * 2009-11-09 2011-05-12 Ira Sanders Treatment of sleep disordered breathing with neurotoxin
EP4375371A3 (en) 2011-05-19 2024-07-31 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
CA2880897C (en) 2012-11-21 2020-01-14 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551473A (en) 1984-04-26 1985-11-05 Schossow George W Method of inhibiting snoring and obstructive sleep apnea
EP0654040A1 (en) * 1992-06-23 1995-05-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
ES2194025T3 (es) * 1993-06-10 2003-11-16 Allergan Inc Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.
JP3238154B2 (ja) * 1993-12-28 2001-12-10 アラーガン・セイルズ・インコーポレイテッド 過度の発汗を軽減するためのボツリヌス毒素含有医薬組成物
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US9354569B2 (en) 2013-06-13 2016-05-31 Lexmark International, Inc. Heat transfer system for a fuser assembly

Also Published As

Publication number Publication date
ES2192880T3 (es) 2003-10-16
CA2353469A1 (en) 2000-06-15
BR9915800A (pt) 2001-09-25
RU2243783C2 (ru) 2005-01-10
PL349334A1 (en) 2002-07-15
NO328762B1 (no) 2010-05-10
KR20010089527A (ko) 2001-10-06
CN1329501A (zh) 2002-01-02
WO2000033863A2 (de) 2000-06-15
HUP0104702A2 (hu) 2002-04-29
JP4700811B2 (ja) 2011-06-15
DE59904569D1 (de) 2003-04-17
NO20012716L (no) 2001-06-01
PL202908B1 (pl) 2009-08-31
HUP0104702A3 (en) 2003-09-29
WO2000033863A3 (de) 2000-11-02
EP1137430B1 (de) 2003-03-12
HK1040636B (zh) 2003-05-30
CZ295769B6 (cs) 2005-11-16
EP1137430A2 (de) 2001-10-04
NO20012716D0 (no) 2001-06-01
DE19856897A1 (de) 2000-06-15
PT1137430E (pt) 2003-07-31
JP2002531516A (ja) 2002-09-24
KR100859556B1 (ko) 2008-09-22
IL143528A0 (en) 2002-04-21
HK1040636A1 (en) 2002-06-21
US6573241B1 (en) 2003-06-03
ATE234108T1 (de) 2003-03-15
DK1137430T3 (da) 2003-06-16
AU3037400A (en) 2000-06-26
AU764744B2 (en) 2003-08-28
CN1186095C (zh) 2005-01-26
IL143528A (en) 2008-04-13

Similar Documents

Publication Publication Date Title
CZ20012058A3 (cs) Terapeutická látka k potlačení chrápání
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
BG100974A (en) Vaccines against papillomavirus
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
NZ507717A (en) Derivatives of pneumococcal choline binding proteins for vaccines
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
RU2001116080A (ru) Терапевтический агент для подавления шумов храпа
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
WO2002047715A3 (en) Compositions of peptide crystals
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
CA2188284A1 (en) Group a streptococcal polysaccharide immunogenic compositions and methods
WO2002038775A3 (en) METHODS FOR PRODUCING AND PURIFYING RECOMBINANT α-L-IDURONIDASE
AU1436699A (en) The use of polyols in combating yeast infection and polyol preparations for saiduse
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
CA2253287A1 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
WO1994008613A3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy
TR199900770T2 (xx) Nazal poliplerin tedavisinde bir H+, K+-ATPase'�n kullan�lmas�.
WO2002026245A3 (en) Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
WO1996030042A3 (en) Methods of treating inflammation and compositions therefor
EP0955366A4 (en) ANTIGENIC PROTEIN FROM MALASSEZIA
AU7030700A (en) Preparation of highly pure toxin fragments
EP0831869A4 (en) DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS
EP0199568A3 (en) Method for purifying interferon and composition of matter produced thereby
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20111210